Following discussions with the FDA, it was decided that the NDA resubmission would seek accelerated approval for elamirpretide on the basis of improvement in knee extensor muscle strength.

“Compared with placebo, stapokibart rapidly and significantly reduced nasal polyp size, improved the main symptoms of rhinosinusitis, reduced overall sinus inflammation, and enhanced quality of life ...

HealthDay News — For patients 50 years or older at high cardiovascular risk without diabetes or prior stroke, an intensive systolic blood pressure (SBP) target (<120 mm Hg) seems cost-effective at ...

Significant decrease seen in serum levels of vascular endothelial growth factor and interleukin-1 receptor antagonist at 12 months.

HealthDay News — Quitting smoking is associated with recovery from substance use disorder (SUD), according to a study published online August 13 in JAMA Psychiatry.

The sNDA for acquired hyothalamic obesity is supported by data from the randomized, double-blind, placebo-controlled phase 3 TRANSCEND trial.

Health systems can use electronic health record data to target households rather than just individuals, authors say.

The Signos Glucose Monitoring System is a mobile device application that receives data from an OTC integrated continuous glucose monitor, the Dexcom Stelo Biosenor.